Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $722 | In Stock |
Description | Glembatumumab vedotin (CDX-011) is an antibody-activated small molecule coupling, Glembatumumab vedotin has potent anticancer effects and can be used in the study of triple negative breast cancer (TNBC). |
In vitro | Glembatumumab vedotin binds to GPNMB on tumor cells, and the complex is internalized. Within the lysosomal compartment, the protein linker containing monomethyl auristatin E (MMAE) is enzymatically cleaved, releasing MMAE. MMAE inhibits microtubules, leading to cell cycle arrest and subsequent tumor cell death[1]. Glembatumumab vedotin exhibits cytotoxic activity against osteosarcoma cells at concentrations ranging from 1 to 125 μg/mL over a 96-hour period[2]. |
In vivo | In human SK-MEL-2 and SK-MEL-5 melanoma xenograft models, Glembatumumab vedotin (CR011-vcMMAE) demonstrates both short-term antitumor effects (inhibiting tumor growth) and long-term effects (complete regression) when administered via intravenous injection at doses ranging from 1.25 to 80 mg/kg, every 4 days, for a duration of 16 days[3]. |
Alias | CR011-vcMMAE, CR 011 ADC, CDX-011 |
Cas No. | 1182215-65-1 |
Storage | keep away from direct sunlight Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.